Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Octagam / Panzyga (immunoglobulin portfolio) by Quarter
Octagam / Panzyga (immunoglobulin portfolio) — Worldwide reported YoY (%) (%)
Pfizer Octagam / Panzyga (immunoglobulin portfolio): 43.0% in Q2 2026.
Latest, Q2 2026
43.0%
Period ended Jun 28, 2026
Change on a year earlier
–
History
14 quarters
Since Q1 2022
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
“|| Octagam | 138 | 96 | 43% | 43% | 138 | 96 | 43% | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Octagam / Panzyga (immunoglobulin portfolio) (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/octagam-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.